PROTEINS FOR THE TREATMENT OF EPITHELIAL BARRIER FUNCTION DISORDERS
Patent Information
- Application Number
- DE602018091727
- Authority / Receiving Office
- DE · DE
- Patent Type
- Patents
- Current Assignee / Owner
- Priority Date
- 2017-12-28
- Filing Date
- 2018-04-06
- Publication Date
- 2026-06-10
- Estimated Expiration
- 2038-04-06
AI Technical Summary
Current IBD therapeutics primarily target inflammation without addressing the breakdown of intestinal barrier function, which is crucial for disease progression, and there is a need for stable protein therapeutics that enhance epithelial barrier integrity and reduce inflammation.
Development of novel protein therapeutics with specific amino acid sequences, such as SEQ ID NO:19 and variants, that promote epithelial barrier function, reduce inflammation, and are stable during manufacturing and storage, formulated in pharmaceutical compositions for targeted delivery.
The protein therapeutics enhance epithelial barrier integrity, reduce intestinal inflammation, and modulate cytokine levels, effectively treating inflammatory bowel diseases like Crohn's disease and ulcerative colitis, with improved stability and efficacy.